https://www.genengnews.com/topics/cancer/gilead-to-acquire-tubulis-for-up-to-5b-expanding-cancer-adc-capabilities/
Gilead to Acquire Tubulis for Up to $5B, Expanding Cancer ADC Capabilities
Apr 7, 2026 - Gilead Sciences has agreed to acquire German-based Tubulis for up to $5 billion, the companies said today, in a deal designed to expand the buyer’s...
gileadacquiretubulisexpandingcancer
https://www.htgf.de/portfolio/htgffamily/tubulis/
Tubulis
May 15, 2026 - Tubulis ist ein Life Science Startup in München ✓ Teil der #HTGFFamily seit 2020 ✓ HTGF Manager: Dr. Frank Hensel ✓ Hier mehr lesen
tubulis
https://www.htgf.de/gilead-to-acquire-htgf-backed-biotech-tubulis/
Gilead to Acquire HTGF-Backed Biotech Tubulis
Apr 7, 2026 - The transaction marks HTGF's highest-valued exit to date and the third unicorn exit in HTGF's life sciences portfolio.
gileadacquirehtgfbackedbiotech
https://tubulis.com/privacy-statement/
Privacy Statement - Tubulis
Feb 24, 2026 - Welcome to Tubulis GmbH (referred to as “Tubulis”, “we”, “us” or “our” throughout this Privacy Notice). We are very delighted that you have shown interest in...
privacy statementtubulis
https://tubulis.com/
Startseite - Tubulis
May 22, 2026 - Tubulis is now part of Gilead Sciences www.gilead.com NEWS April 21 Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant...
startseitetubulis
https://tubulis.com/news/tubulis-adds-steve-kelsey-as-independent-director-to-its-advisory-board/
Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board - Tubulis
MUNICH, GERMANY, January 27, 2026 – Tubulis today announced the appointment of Steve Kelsey, MD, as independent director to its Advisory Board. Dr. Kelsey,...
tubulisaddsstevekelseyindependent
https://tubulis.com/news/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline/
Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next...
Apr 7, 2026 - Foster City, Calif., and Munich, Germany – April 7, 2026 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to...
antibody druggileadacquiretubulisadding
https://tubulis.com/disclaimer/
Disclaimer - Tubulis
Aug 30, 2023 - No warranties This website is provided “as is” without any representations or warranties, express or implied. WE make no representations or warranties in...
disclaimertubulis
https://tubulis.com/imprint/
Imprint - Tubulis
Sep 8, 2023 - Legal Disclosure Information in accordance with section 5 TMG Tubulis GmbHAm Klopferspitz 19 a82152 Planegg-MartinsriedGermany Commercial register...
imprinttubulis
https://tubulis.com/newsevents/
News & Events - Tubulis
May 28, 2024 - News Our latest Press Releases More News EVENTS Meet Tubulis live More Events
news eventstubulis
https://eqtgroup.com/about/current-portfolio/tubulis
Tubulis | EQT Portfolio
Tubulis is a biotechnology company developing novel Antibody Drug Conjugates for solid tumours.
tubuliseqtportfolio
https://tubulis.com/news/tubulis-presents-first-clinical-data-from-phase-i-iia-trial-for-tub-040-in-platinum-resistant-ovarian-cancer-proc-at-esmo-2025/
First positive data TUB-040 in ovarian cancer · Tubulis News
Oct 20, 2025 - Tubulis announces positive first-in-human data for TUB-040, it's lead antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer.
ovarian cancerfirstpositivedatatub
https://tubulis.com/news/tubulis-to-present-phase-i-iia-trial-data-for-adc-candidate-tub-040-in-platinum-resistant-ovarian-cancer-in-rapid-oral-presentation-at-asco-2026/
Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant Ovarian...
Apr 21, 2026 - MUNICH, GERMANY, April 21, 2026 – Tubulis today announced that an abstract covering current clinical trial data from its ongoing Phase I/IIa NAPISTAR 1-01...
trial datatubulispresentphaseiia
https://tubulis.com/about/
Meet the Team behind Tubulis - Tubulis
Mar 4, 2026 - We are supported by a strong scientific and entrepreneurial network Together, the team has built a strong collaborative network bringing together expertise in...
team behindmeettubulis
https://tubulis.com/our-pipeline/
Enabling durable treatment options in oncology - Tubulis
Jan 2, 2026 - We are building a pipeline of uniquely-assembled, highly stable ADCs by leveraging proprietary conjugation, linker and payload technologies that enable us to...
treatment optionsenablingdurableoncologytubulis
https://tubulis.com/publications/
Publications Archive - Tubulis
publications archivetubulis
https://tubulis.com/investors/
Supported by highly experienced investors - Tubulis
highly experiencedsupportedinvestorstubulis
https://www.doppelgaenger.io/anthropic-mythos-satoshi-nakamoto-enttarnt-openai-ipo-in-gefahr-tubulis-5-mrd-exit-552/
Anthropic Mythos | Satoshi Nakamoto enttarnt? | OpenAI IPO in Gefahr | Tubulis $5 Mrd. Exit #552 -...
Apr 11, 2026 - Gilead übernimmt das Münchner Biotech-Startup Tubulis für $5 Mrd. Amazon macht $15 Mrd. KI-Umsatz und $20 Mrd. mit eigenen Chips. Anthropic stellt Mythos vor,
satoshi nakamotoanthropicmythosopenaiipo
https://tubulis.com/technology/
Technology-Page - Tubulis
Oct 13, 2025 - Harnessing the Power of ADCs Our technologies P5 Tubutecan Alco5 P5 Conjugation The Next Generation Conjugation for High DAR ADCs Our P5 Conjugation...
technologytubulis